Elif Yilmazel Ucar
Overview
Explore the profile of Elif Yilmazel Ucar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Celebi Sozener Z, Oguzulgen I, Ozalp Ates F, Baccioglu A, Argun Baris S, Ediger D, et al.
J Asthma
. 2025 Feb;
:1-11.
PMID: 39932533
Objective: The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. Methods: This research is a...
2.
Arslan B, Turk M, Hayme S, Aydin O, Gokmen D, Koycu Buhari G, et al.
Clin Transl Allergy
. 2025 Jan;
15(1):e70018.
PMID: 39865387
Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective:...
3.
Beyaz S, Erdinc M, Hayme S, Aslan A, Aydin O, Gokmen D, et al.
Allergol Immunopathol (Madr)
. 2025 Jan;
53(1):12-25.
PMID: 39786871
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This...
4.
Aksakal A, Karaca Ural Z, Jalal L, Cil G, Kerget B, Araz O, et al.
Eurasian J Med
. 2024 Dec;
56(3):213-215.
PMID: 39655878
No abstract available.
5.
Gemicioglu B, Gokmen D, Can A, Sevinc C, Oguzulgen I, Soyyigit S, et al.
Respir Med
. 2024 Dec;
236:107883.
PMID: 39617354
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims...
6.
Aksakal A, Kerget B, Ozkan H, Araz O, Yilmazel Ucar E, Saglam L, et al.
Tuberk Toraks
. 2024 Apr;
72(1):48-58.
PMID: 38676594
Introduction: The gold standard treatment for obstructive sleep apnea syndrome (OSAS) is positive airway pressure therapy (PAP) treatments. PAP treatments reduce complications by reducing apnea and hypopnea attacks by creating...
7.
Ozmen K, Meral M, Kerget B, Yilmazel Ucar E, Saglam L, Ozmen M
Cureus
. 2024 Mar;
16(3):e56003.
PMID: 38476506
Background: Coronavirus disease 2019 (COVID-19) causes various signs and symptoms, especially lung involvement, during acute infection and in the long term. In this study, we evaluated the follow-up results of...
8.
Ergul E, Yilmazel Ucar E, Araz O, Aksakal A, Kerget B, Saglam L
Tuberk Toraks
. 2023 Dec;
71(4):390-399.
PMID: 38152009
Introduction: Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy...
9.
Karadogan D, Yilmazel Ucar E, Yavuz Y, Baccioglu A, Ozturk A, Bozkurt N, et al.
J Asthma
. 2023 Dec;
61(6):539-549.
PMID: 38060588
Objective: The older adult population in Turkey has increased by 22.6% in the last 5 years, and the characteristics of such patients with asthma remain uninvestigated. Therefore, we aimed to...
10.
Kizilirmak D, Yilmaz Kaya Z, Gokcimen G, Havlucu Y, Ozyurt B, Gundogus B, et al.
Cancer Epidemiol
. 2023 Oct;
87:102480.
PMID: 37897971
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Before beginning lung cancer treatment, it is necessary to complete procedures such as suspecting lung cancer, obtaining a pathologic...